AVITA Medical Reports 67% Revenue Growth in Q1 2025, Expands Product Portfolio
核心洞察
AVITA Medical reported Q1 2025 commercial revenue of $18.5 million, representing a 67% increase compared to the same period in 2024, with a strong gross profit margin of 84.7%.
The company has transformed from a single-product burn-focused company to a multi-product platform with the launch of RECELL GO mini (搜索) in February and nationwide rollout of Cohealyx (搜索) in April 2025.
AVITA Medical reaffirmed its 2025 guidance, projecting full-year commercial revenue between $100-106 million, with expectations to generate free cash flow in the second half of 2025 and achieve GAAP profitability by Q4.
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) reported strong financial results for the first quarter of 2025, with commercial revenue reaching $18.5 million, representing a 67% increase compared to the same period in 2024. The company maintained a robust gross profit margin of 84.7% as it continues its transformation from a single-product burn treatment company to a diversified acute wound care platform.
Strong Q1 Performance Driven by Portfolio Expansion
The Valencia, California-based company's significant revenue growth was primarily attributed to deeper penetration within existing customer accounts, acquisition of new accounts for full-thickness skin defect treatments, and contributions from recent product launches. The company's RECELL (搜索) product line maintained a gross margin of 86.4% for the quarter.
"We've transformed from a single-product, burn-only company into an integrated, multi-product platform positioned to lead in therapeutic acute wound care," said Jim Corbett, Chief Executive Officer of AVITA Medical. "With the February rollout of RECELL GO mini (搜索) and the nationwide launch of Cohealyx (搜索) on April 1, our portfolio now addresses a U.S. market opportunity that has expanded from $455 million to more than $3.5 billion."
The company's expanded product portfolio now includes:
- RECELL GO: The company's core system for burn and trauma centers
- RECELL GO mini: A purpose-built solution designed for smaller wounds, launched in February 2025
- Cohealyx: An AVITA Medical-branded collagen-based dermal matrix, launched nationwide on April 1, 2025
- PermeaDerm: A biosynthetic wound matrix for which AVITA holds exclusive U.S. distribution rights
Financial Details and Outlook
Despite the strong revenue growth, AVITA Medical reported a net loss of $13.9 million, or $0.53 per basic and diluted share, for Q1 2025. This represents an improvement compared to a net loss of $18.7 million, or $0.73 per share, in the same period in 2024.
Total operating expenses for the quarter were $27.5 million, compared to $26.8 million in Q1 2024. The increase was primarily due to a $2.2 million rise in sales and marketing expenses associated with the company's expanded commercial organization. This was partially offset by a $2.6 million decrease in general and administrative expenses.
The company ended the quarter with approximately $25.8 million in cash, cash equivalents, and marketable securities. AVITA Medical secured a waiver of the first quarter trailing 12-month revenue covenant under its credit agreement with OrbiMed (搜索) in exchange for a waiver fee.
AVITA Medical reaffirmed its previously issued guidance for full-year 2025:
- Commercial revenue is expected to be in the range of $100 to $106 million, reflecting growth of approximately 55% to 65% compared to full-year 2024
- The company expects to generate free cash flow in the second half of 2025
- GAAP profitability is anticipated in the fourth quarter of 2025
Commercial and Regulatory Priorities
AVITA Medical outlined several key priorities for 2025, including:
- Driving adoption of RECELL GO across burn and trauma centers
- Expanding adoption of RECELL GO mini within trauma centers, particularly for smaller wounds in high-volume settings
- Increasing awareness and adoption of Cohealyx in acute wound care
- Leveraging the redesigned commercial model to accelerate adoption across the product portfolio
- Developing clinical data for Cohealyx to support efficacy and cost savings claims
- Supporting PermeaDerm adoption through commercial efforts and ongoing clinical studies
- Completing the transfer of PermeaDerm manufacturing to AVITA Medical's in-house facility
- Obtaining CE mark approval for RECELL GO in the European Union, expected by mid-2025
"Our multi-product platform equips clinicians with innovative tools that integrate smoothly into existing workflows, and together with our commercial field transformation, they position AVITA for scalable, long-term growth," Corbett added.
Upcoming Investor Event
The company announced it will host an Acute Wound Care Showcase 2025 on May 13, a virtual event highlighting AVITA Medical's integrated approach to therapeutic acute wound care. The showcase will feature presentations from company executives, insights from treating surgeons and nurses, and testimonials from patients treated with AVITA Medical's technologies.
About AVITA Medical
AVITA Medical is a therapeutic acute wound care company delivering technologies designed to optimize wound healing and accelerate patient recovery. The company's flagship RECELL (搜索) System is FDA-approved for treating thermal burn wounds (搜索) and full-thickness skin defects (搜索). RECELL utilizes a patient's own skin to create Spray-On Skin Cells, providing an innovative solution for improved clinical outcomes.
In the U.S., AVITA Medical holds exclusive rights to market Cohealyx (搜索) and PermeaDerm (搜索). Internationally, the RECELL (搜索) System is approved for various applications including burns and full-thickness skin defects (搜索), with regulatory approvals in Australia, Europe, and Japan.